#Australia #Melbourne #Everest Medicines #Dimerix #DMX-200

Dimerix Partners with Everest Medicines for DMX-200

In a significant collaboration, Dimerix Limited has announced an exclusive license agreement with Everest Medicines, allowing Everest to commercialize DMX-200 across Greater China, South Korea, and parts of Southeast Asia for the treatment of Focal Segmental Glomerulosclerosis (FSGS). This partnership aims to address an urgent medical need in a region where approximately 500,000 to 1 million individuals are estimated to be affected by this rare kidney disease.

The Importance of DMX-200

DMX-200 is a drug under development that acts as a small molecule inhibitor of the chemokine receptor 2 (CCR2). It is currently undergoing a pivotal Phase 3 trial named ACTION3, which is designed to assess its efficacy in treating adults with FSGS. FSGS is characterized by progressive scarring in the kidney's filtering units, which can lead to heavy proteinuria and a decline in kidney function.

The ACTION3 trial has successfully recruited patients across 21 countries, including several in the licensed territories. Initial results have indicated that DMX-200 performs better than placebo in reducing proteinuria, and there have been no safety concerns identified during the trial's reviews.

Strategic Financial Terms

In exchange for this exclusive licensing agreement, Dimerix stands to receive an upfront payment of $10 million, with additional milestone payments totaling potentially up to $330 million tied to specific developmental and regulatory achievements, along with tiered royalties from net sales estimated between 10% to 15%. Overall, through this partnership and previous agreements, Dimerix could benefit from potential total payments nearing $1.9 billion.

This agreement marks the fifth licensing deal for DMX-200, showcasing Dimerix's progressive strategy for expanding its drug's reach. The collaboration with Everest is expected to boost patient access significantly in Asian markets, recognizing the unmet needs for effective treatments in the region.

Dimerix's Commitment to Research

Dimerix will continue to finance and conduct the ongoing ACTION3 study, while Everest will handle regulatory submissions and commercialization activities in the shared markets. A Joint Steering Committee comprising members from both companies will be established to ensure seamless collaboration on the drug’s development and market strategies.

Dr. Nina Webster, CEO of Dimerix, expressed enthusiasm for the partnership, emphasizing the importance of Everest’s expertise in treating rare renal diseases. “This collaboration significantly expands the potential reach of DMX-200 into a large and underserved patient population,” she mentioned, reinforcing their commitment to providing treatment options to those affected by FSGS globally.

Yifang Wu, Chairman of Everest Medicines, highlighted the significance of addressing the substantial unmet medical needs faced by FSGS patients in China, noting the urgency for new targeted treatments.

Looking Ahead

As the completion of the ACTION3 trial approaches, the results from DMX-200 could pave the way for a new treatment paradigm in managing FSGS, a disease that has long lacked effective therapeutics. The urgency for innovative solutions in this field has never been more evident.

Dimerix's strategic decision to collaborate with a specialized commercial partner like Everest Medicines is pivotal as the healthcare landscape rapidly evolves, particularly in regions that have been historically underserved. This partnership not only promises to bring needed therapies to patients but could also strengthen Dimerix's position as a leader in developing treatments for inflammatory kidney diseases.

For more details about DMX-200 or to keep current with Dimerix’s advancements, stakeholders can visit their official website or follow updates through their social media channels.